Patent ID: 6894048

Claim:
A method for treating a patient having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazoleproprionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder, a compound of Formula I: wherein R 1 , R 2 , R 3 and R 4 are independently H, HO, R 11 O—, halogen C1-C3-alkyl, CF 3 , R 12 CO 2 —, R 12 O 2 C—, R 12 CO—, R 12 CONH—, R 12 NHCO—, R 12 NHCO 2 —, R 12 OCONH—, R 12 O 2 S—, R 12 OS—, or R 13 R 14 N—; or R 1 and R 2 , or R 2 and R 3 , or R 3 and R 4 taken together can be —SCH 2 S—, —SCH 2 O—, —OCH 2 S—, —SCH 2 CH 2 S—, —SCH 2 CH 2 O—, or —OCH 2 CH 2 S—; wherein at least one of R 1 , R 2 , R 3 and R 4 must be a C1-C3-alkylthio group, R 5 and R 6 are independently H, C1-C6-alkyl, C3-C6-alkenyl, C3-C6-cycloalkyl, or phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents selected from the group consisting of C1-C3-alkyl, halogen, R 11 O—, CF 3 , R 12 O 2 S—, R 12 OS—, R 12 CO, R 12 CO 2 —, R 12 O 2 C—, R 12 CONH—, R 12 NHCO—, R 12 NHCO 2 —, R 12 OCONH—, and R 13 R 14 N—; or R 5 and R 6 taken together can be C3-C6-cycloalkyl; R 7 is R 13 R 14 NCO—, R 13 R 14 NCS—, R 13 R 14 N(HCR 15 )—, R 15 OCO—, R 13 CO—, R 13 R 14 NCH 2 CO—, R 12 O 2 C—(CH 2 ) n —, R 13 R 14 NCO—(CH 2 ) n —, NC—(CH 2 ) n —, H, C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl; or R 6 and R 7 taken together can be —(CH 2 ) m CH 2 (R 13 )NCO—, —(CH 2 ) m CH 2 OCO—, or —(CH 2 ) m CH 2 CH 2 CO—; R 8 and R 9 are independently H, R 13 R 14 N—, R 13 R 14 N(HCR 15 )—, R 12 HNCO—, or R 12 CONH—; R 10 is H, halogen, HO, R 11 O—, R 13 R 14 N—, C1-C3-alkyl, CF 3 , R 12 CO 2 —, R 12 CO—, or R 12 CONH—; R 11 is C1-C3-alkyl; R 12 is H or C1-C3-alkyl; R 13 and R 14 are independently H, C1-C10-alkyl, C1-C6-perfluoroalkyl, C3-C10-alkenyl, or C3-C6-cycloalkyl; or R 13 and R 14 taken together can be C3-C6-cycloalkyl; R 15 is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl; n is 1 to 6; m is 0 to 2; and pharmaceutically acceptable salts thereof; wherein R 8 and R 9 cannot be both be H, in combination with a pharmaceutically acceptable carrier.